(Press-News.org) NEW YORK (March 17, 2015)--A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.
PaMZ is a three-drug regimen comprised of two candidate drugs that are not yet licensed for use against TB: pretomanid (Pa), formerly known as PA-824, and moxifloxacin (M), and one antibiotic, pyrazinamide (Z), which is approved for use in TB treatment today. The therapy is intended for those patients whose TB infections are sensitive to the three drugs, including people with drug-sensitive and multidrug-resistant TB (MDR-TB).
"The results of this trial show the potential for the PaMZ regimen to improve treatment for tuberculosis," said Rod Dawson, MD, head of the Centre for TB Research Innovation at the University of Cape Town, South Africa, and lead author of the paper. "Especially noted is the fact that PaMZ may have a unique application as a potentially shorter, injection-free regimen for a select sub-group of patients with MDR-TB."
The Phase 2b trial, known as NC-002, tested PaMZ in an eight-week study that enrolled more than 200 patients and took place at eight sites in South Africa and Tanzania. Nearly twice (71 percent) as many TB patients treated with PaMZ had no TB in their sputum when cultured at the end of the 2-month course of the trial compared to patients treated with standard therapy (38 percent). These results are based on liquid culture, the most sensitive diagnostic method available.
Patients in the arm of the trial that tested the effectiveness of PaMZ on MDR-TB responded similarly to those with drug-sensitive TB. However, the study group for MDR-TB was small. When added to evidence from pre-clinical and earlier studies, PaMZ shows the potential to treat drug-sensitive TB and some patients with MDR-TB in four to six months.
"PaMZ is the first regimen under development to treat both drug-sensitive TB and MDR-TB," said Mel Spigelmen MD, President and CEO of TB Alliance, the trial's sponsor. "If successful, PaMZ could be a shorter, simpler, and safer treatment that would enable the scale-up of treatment."
Twenty percent of the TB patients enrolled in NC-002 also were co-infected with HIV. The PaMZ regimen appeared to be effective independent of HIV status.
Limitations in standard TB treatment remain a strong barrier to TB control. The treatment and cure of a typical case of drug-sensitive TB currently takes between six and nine months. People with drug-resistant TB require a minimum of 18 to 24 months of treatment. This more extensive therapy requires more than 14,000 pills and daily injections for at least 6 months. The long duration of MDR-TB treatment, combined with the pain and side effects that treatment causes, are major obstacles to access. Only 20 percent of all MDR-TB patients receive any treatment, and of those who do, less than half (48 percent) will be cured, according to the World Health Organization's 2014 Global Report.
On the basis of these and other data, TB Alliance and its partners have launched a global phase 3 clinical trial named STAND (Shortening Treatment by Advancing Novel Drugs) in patients who are currently considered to have either drug-sensitive or multidrug-resistant TB.
Enrollment has begun in the STAND trial. STAND researchers expect to enroll 1,500 patients in 15 countries in Africa (Kenya, South Africa, Tanzania, Uganda, Zambia), Asia (China, Malaysia, Philippines, Thailand), Caribbean (Haiti), Eastern Europe (Georgia, Russia, Ukraine), and Latin America (Brazil, Peru) in this study. PaMZ will be tested in STAND as a 4- and 6-month treatment for drug-sensitive TB and a 6-month treatment for drug-resistant TB, and also enroll those co-infected with HIV. Each patient will be followed for two years starting from the beginning of treatment. The STAND trial partners with many of the communities in which the study is conducted through its robust community engagement program.
If successful in this Phase 3 trial, the PaMZ regimen would eliminate the need for injectable drugs and reduce the cost of MDR-TB therapy by more than 90 percent in those patients whose TB organisms are sensitive to the three drugs. It also promises to be compatible with commonly used HIV drugs, helping the millions of people co-infected with TB/HIV.
INFORMATION:
About TB Alliance
The Global Alliance for TB Drug Development (TB Alliance) is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, European Commission, Global Health Innovative Technology Fund, Irish Aid, National Institute of Allergy and Infectious Disease, UNITAID, United Kingdom Department for International Development, United States Agency for International Development, and the United States Food and Drug Administration. For more information please visit tballiance.org.
Chemical changes that occur in tree leaves after being attacked by insects and mammals can impact nearby streams, which rely on fallen plant material as a food source, report scientists from the University of Chicago Department of Ecology and Evolution. The study, published March 17 in the journal Proceedings of the Royal Society B, shows how interactions between terrestrial and aquatic ecosystems are an essential part of understanding ecological responses to climate change.
Graduate student Sara Jackrel and Timothy Wootton, PhD, professor in the Department of Ecology ...
Longer duration of breastfeeding is linked with increased intelligence in adulthood, longer schooling, and higher adult earnings, a study following a group of almost 3500 newborns for 30 years published in The Lancet Global Health journal has found.
"The effect of breastfeeding on brain development and child intelligence is well established, but whether these effects persist into adulthood is less clear,"* explains lead author Dr Bernardo Lessa Horta from the Federal University of Pelotas in Brazil.
"Our study provides the first evidence that prolonged breastfeeding ...
Alteplase is a tissue plasminogen activator (tPA) that helps to disperse blood clots in a process called thrombolysis.
Most major stroke guidelines support use of alteplase up to 4.5 hours after stroke onset, but Dr Brian Alper and colleagues believe that current guidance is based on uncertain evidence and they call for urgent reconsideration of the available data to guide policy decisions.
The UK regulator, the Medicines and Healthcare Regulatory Agency (MHRA), is planning to analyse all relevant sources of evidence and reassess the balance of benefits and risks for ...
Previous research among young and older adults has suggested that the context in which drinking occurs may contribute to specific alcohol-related problems, such as aggression, risky sex, and drinking and driving. However, little is known about how young drinkers select drinking contexts. A longitudinal study of drinking patterns, and demographic and psychosocial characteristics associated with youth drinking in different contexts, has found that where youth drink alcohol varies by characteristics such as age, gender, drinking frequency, smoking, and deviant behaviors.
Results ...
Both the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), and the International Statistical Classification of Diseases and Related Health Problems, 10th Edition (ICD-10) have established diagnostic criteria for alcohol use disorders (AUDs). While the DSM is widely used by clinicians, the U.S. Centers for Medicare and Medicaid Services has recently called for providers to bill for services using ICD-10 designations. Given the ramifications for who will and will be not eligible for treatment, this study compares the two diagnostic approaches, finding ...
A new study has examined genetic and environmental influences underlying alcohol use.
Results show that genetic effects on the amount of alcohol use appear to be greater in low socioeconomic-status (SES) conditions.
Shared environmental effects tended to increase in high-SES conditions, and non-shared environmental effects tended to decrease with SES.
Research on genetic and environmental influences underlying alcohol use has thus far failed to uncover specific causes, likely because genetic and environmental influences vary by context. A study of the moderating ...
DALLAS, March 17, 2015 -- Your heart health, which is optimal for most of us at birth, can decline substantially with unhealthy childhood behaviors, according to research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
"Our findings indicate that, in general, children start with pretty good blood pressure," said Donald M. Lloyd-Jones, M.D., Sc.M., senior author of the study and professor and chair of preventive medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. "But if they have a horrible ...
March 17, 2015 -- Female community health extension workers deployed to a remote rural community in northern Nigeria led to major and sustained increases in service utilization, including antenatal care and facility-based deliveries, according to latest research by Columbia University's Mailman School of Public. The research also showed that providing a rural residence allowance in addition to a standard salary helped recruit and retain female workers. Other key components to the program's success were posting workers in pairs to avoid isolation, ensuring supplies and transportation ...
Archaeologists from The Field Museum in Chicago, IL and Shandong University (Jinan, China) have investigated the historical processes leading up to China's political unification through the juxtaposition of macro- and micro-scale analysis. The study offers new perspectives on how human impacts of infrastructural investments, interactive technologies, social contracts, and ideologies that were implemented during the Qin and Han Dynasties and before have helped establish the rough spatial configuration of what is today China.
Why humans cooperate in large social groupings ...
The genome of a cell is under constant attack, suffering DNA damage that requires an army of repair mechanisms to keep the cell healthy and alive. Understanding the behavior of the enzymes defending these assaults helps determine how - and where - cancer gets its foothold and flourishes. New research published in an Advance Online Publication of Nature Structural & Molecular Biology shows that one of these enzymes - human DNA polymerase theta (POLQ) - may be a promising drug therapy target for inhibiting breast cancer.
"The human genome encodes more than 15 different ...
